Search

Your search keyword '"gc/ms"' showing total 3 results
Start Over Descriptor "gc/ms" Publication Type Books
Sorry, I don't understand your search. ×
3 results on '"gc/ms"'

1. (Mass Spectrometric) Non Target Screening-Techniques and Strategies.

Author

Letzel, Thomas and Letzel, Thomas

Subjects
2-methylfuran, 2DGC, GC-APCI, GC-API, GC-APLI, GC-APPI, GC-MS, GC/MS, Ganoderma lingzhi, HPLC, Ionization, LC/IT-TOF-MS, MS subtraction, MS/MS, NSAIDs, NTS strategies, NTS techniques (separation, ionization, and detection), UPLC-qToF, amino acids, analytical, azoxystrobin, cheminformatics, collision cross section, computational mass spectrometry, corticosteroids, data analysis, database, decision making, developmental stages, emerging contaminants, equation, furan, gas chromatography ion mobility spectroscopy (GC-IMS), glutathione, glutathione conjugate, glycomics, glycoproteomics, glycosylation, high-resolution mass spectrometry, higher-energy collisional dissociation, in silico docking, ion mobility spectrometry, lipidomics, machine learning, marker compounds, mass spectrometry, metabolomics, micropollutant fingerprint, network pharmacology, non-small cell lung cancer, non-target screening, non-targeted screening, non-targeted screening (NTS) using machine learning, nontargeted screening, nucleosides, open access software, organic micropollutants, persistent organic pollutants, pharmaceutical and personal care products, plant-derived food, proteomics, quantification, review, small molecule fragmentation, software, solid phase extraction, spectral deconvolution, statistical analysis, target gas, tea, triple quadrupole, ultraviolet photodissociation, untargeted analysis, untargeted metabolomics, urban waters, urinary metabolites, volatile organic compounds (VOCs), volatilomics, water quality, α-glucosidase inhibitory activity
Abstract

Summary: (Mass spectrometric) non-target screening is a preferably comprehensive and untargeted (predominantly organic molecules detecting) approach combining (robust) analytical measurements with adapted data evaluation concepts, systematic compound identification workflows, and statistical data interpretation. It is well suitable for the identification of new, unexpected and/or unknown organic compounds as well as monitoring 'molecular fingerprints' and profiling 'process-relevant' molecules via statistical methods. In recent years, 14 articles in various disciplines were published and presented in this Special Issue, whereby it contains 4 peer-reviewed review articles and 10 peer-reviewed research articles dealing with non-target screening strategies and solutions.

2. Radiation Response Biomarkers for Individualised Cancer Treatments.

Author

Badie, Christophe, Badie, Christophe, and Rutten, Eric Andreas

Subjects
Medicine, GC/MS, IMRT, PBMCS, RILF, RILI, STING, abscopal effect, biodosimetry, biological dosimetry, biomarker, biomarkers, cGAS, cancer, carbon-ion radiotherapy, chromosomal instability, chromosome aberrations, circulating biomarkers, circulating tumour cells, clonogenic assays, dicentric assay, exosomes, extracellular vesicles, gamma H2AX foci assay, genotoxicity tests, head and neck cancer, head-and-neck tumors, health surveillance analyses, human blood, immune infiltrate, immune system, immunotherapy, individual radiosensitivity, inflammation, inversions, ionizing radiation, late effects, liquid biopsy, lung cancer, machine learning, metabolomics, methods, microRNA, microRNAs, micronuclei, micronucleus assay, n/a, normal tissue, normal tissue toxicity, personalized medicine, plating, pneumonitis, predictive tests, prostate cancer, protein, proteomics, radiation, radiation-induced lung fibrosis, radiation-induced lung injury, radiosensitivity, radiotherapy, radiotherapy monitoring, relative biological effectiveness, serum, squamous cell carcinoma, stroma, telomeres, tumour microenvironment, uterine cervical cancer
Abstract

Summary: Personalised medicine is the next step in healthcare, especially when applied to genetically diverse diseases such as cancers. Naturally, a host of methods need to evolve alongside this, in order to allow the practice and implementation of individual treatment regimens. One of the major tasks for the development of personalised treatment of cancer is the identification and validation of a comprehensive, robust, and reliable panel of biomarkers that guide the clinicians to provide the best treatment to patients. This is indeed important with regards to radiotherapy; not only do biomarkers allow for the assessment of treatability, tumour response, and the radiosensitivity of healthy tissue of the treated patient. Furthermore, biomarkers should allow for the evaluation of the risks of developing adverse late effects as a result of radiotherapy such as second cancers and non-cancer effects, for example cardiovascular injury and cataract formation. Knowledge of all of these factors would allow for the development of a tailored radiation therapy regime. This Special Issue of the Journal of Personalised Medicine covers the topic of Radiation Response Biomarkers in the context of individualised cancer treatments, and offers an insight into some of the further evolution of radiation response biomarkers, their usefulness in guiding clinicians, and their application in radiation therapy.

Catalog

Books, media, physical & digital resources
See catalog results